Citius Pharmaceuticals said new data show LYMPHIR responders with relapsed or refractory CTCL sustained improvements in skin-related quality-of-life measures. T

Citius Pharmaceuticals said new data show LYMPHIR responders with relapsed or refractory CTCL sustained improvements in skin-related quality-of-life measures. The findings were presented at EORTC-CLTG 2026 and add to the drug’s evidence base in CTCL.